New eye drops for nearsightedness pass early safety check

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being clinically healthy * Ability to voluntarily sign an informed consent form (ICF). * Ability and willingness to comply with the scheduled visits according to the intervention plan and other procedures of the study. * Age between 18 and 35. * Absence of history of contact lens use. * Women of childbearing age must agree to continue (starting ≥ 30 days previous to the ICF) the use of a hormonal contraception method of a intrauterine device (IUD) during the period of the study. * Best corrected visual acuity (BVCA) of at least 20/30 (logMAR 0.2) or better in both eyes. * Best near corrected visual acuity (BNVCA) of at least 20/25 (logMAR 0.1) or better in both eyes. * Presenting vital signs within normal parameters. * Presenting an IOP ≥10 and ≤ 21 mmHg Exclusion Criteria: * Using any kind of ophthalmic topical products. * Presenting known allergy or intolerance to any ingrediente of atropine eyedrops or any other derivatives of antimuscarinic agents. * Using any medication of herbolary products (plant extracts, infusions, naturist preparations, homeopathy, etc) through any route of administration * For women: being pregnant, breastfeeding or planning to get pregnant during the period of the study. * Having participated in any clinical study 90 days prior to the inclusion in this study. * Having participated in this clinical study. * Inability to follow the lifestyle considerations of this study. * History of any chronic degenerative disease, including diabetes and hypertension. * Presenting active inflammatory or infectious diseases when entering this study. * Presenting unresolved lesions or trauma when entering this study. * History of any ocular surgery. * History of any surgery, non-ocular, within the previous 3 months of entering this studies. * Being or having an direct family member (spouse, parent/legal guardian, sibling, etc) as employee of the investigation site or the sponsor, who participates directly in this study. Elimination criteria: * Withdraw of ICF. * Adverse event, related or not to the investigation product, that according to the principal investigator and/or the sponsor may affect the integrity of the patient to continue safely with the study's procedures. * Hypersensitivity or lack of tolerance to any of the ingredients used during the study's procedures (fluorescein, lissamine green, tetracaine, etc) * Hypersensitivity or lack of tolerance to the investigation product. * Presenting an adherence to treatment \< 90%, as determined through the subjects diary.